Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003434 · ClinicalTrials.gov registry record · Phase 1
Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer
A Phase 1 study, sponsored by Duke University.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00003434 is a Phase 1 study that was terminated before completion, run by Duke University. The registered enrollment target is 8 participants.
The verdict
NCT00003434, a Phase 1 study, was terminated before completion, sponsored by Duke University.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating patients with stage I, stage II, or stage III pancreatic cancer that has been surgically removed.
Interventions
- BIOLOGICAL carcinoembryonic antigen peptide 1
- BIOLOGICAL hepatitis B antigen peptide
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 1998-06 |
| Est. Completion | 2002-08 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00003434
The ClinicalTrials.gov registry entry for NCT00003434 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which carcinoembryonic antigen peptide 1 is the first listed.
NCT00003434 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00003434 about?
NCT00003434 is a clinical study titled "Biological Therapy in Stage I, Stage II, or Stage III Surgically Resected Pancreatic Cancer". Rational: White blood cells that have been treated with carcinoembryonic antigen peptide-1 may help the body build an immune response to and kill tumor cells that express CEA. Purpose: Phase II trial to study the effectiveness of white blood cells plus carcinoembryonic antigen peptide-1 in treating...
What is the current status of trial NCT00003434?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 1998-06. Estimated completion is 2002-08.
What interventions are being tested in trial NCT00003434?
The interventions under investigation include: carcinoembryonic antigen peptide 1 (BIOLOGICAL), hepatitis B antigen peptide (BIOLOGICAL).
Who is sponsoring clinical trial NCT00003434?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.